Published in J Mol Neurosci on February 19, 2012
Davunetide (AL-108) in Predicted Tauopathies - Pilot Study | NCT01056965
Induced tauopathy in a novel 3D-culture model mediates neurodegenerative processes: a real-time study on biochips. PLoS One (2012) 1.43
Familial Alzheimer's disease modelling using induced pluripotent stem cell technology. World J Stem Cells (2014) 0.84
A high-throughput screening assay for determining cellular levels of total tau protein. Curr Alzheimer Res (2013) 0.83
Isolation and characterization of antibody fragments selective for toxic oligomeric tau. Neurobiol Aging (2014) 0.80
Brain Aggregates: An Effective In Vitro Cell Culture System Modeling Neurodegenerative Diseases. J Neuropathol Exp Neurol (2016) 0.75
Tau downregulates BDNF expression in animal and cellular models of Alzheimer's disease. Neurobiol Aging (2016) 0.75
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A (2001) 11.06
Tau suppression in a neurodegenerative mouse model improves memory function. Science (2005) 8.66
Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol (2008) 6.38
Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science (2001) 6.17
Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature (1999) 5.53
Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron (1993) 3.45
Caspase activation precedes and leads to tangles. Nature (2010) 3.24
The c-jun kinase/stress-activated pathway: regulation, function and role in human disease. Biochim Biophys Acta (2007) 2.83
Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron (2010) 2.68
Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med (2009) 2.39
Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron (2003) 2.17
Domains of tau protein, differential phosphorylation, and dynamic instability of microtubules. Mol Biol Cell (1995) 2.15
Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol (1999) 2.08
Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov (2007) 1.92
GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol Psychiatry (2004) 1.79
Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett (1993) 1.74
Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog Neurobiol (2008) 1.74
Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J Biol Chem (2007) 1.68
Crystal structure of a conformation-selective casein kinase-1 inhibitor. J Biol Chem (2000) 1.59
Accelerated filament formation from tau protein with specific FTDP-17 missense mutations. FEBS Lett (1999) 1.57
Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation. J Cell Sci (1996) 1.49
Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize microtubules. J Neurochem (2004) 1.49
Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci (2006) 1.44
Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J Neurochem (2002) 1.42
Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons. Neurosci Res (1998) 1.41
Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr Alzheimer Res (2005) 1.39
Analysis of tau phosphorylation and truncation in a mouse model of human tauopathy. Am J Pathol (2007) 1.32
Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci (2007) 1.24
Pathways by which Abeta facilitates tau pathology. Curr Alzheimer Res (2006) 1.23
Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. J Neuropathol Exp Neurol (2001) 1.18
Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic. Curr Opin Drug Discov Devel (2008) 1.18
Casein kinase 1 delta phosphorylates tau and disrupts its binding to microtubules. J Biol Chem (2004) 1.11
Soluble tau species, not neurofibrillary aggregates, disrupt neural system integration in a tau transgenic model. J Neuropathol Exp Neurol (2011) 1.10
Casein kinase 1 delta mRNA is upregulated in Alzheimer disease brain. Brain Res (2000) 1.07
Amyloid-beta-induced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and cyclin-dependent kinase 5 expression. J Neurochem (2004) 1.06
AbetaPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576. J Alzheimers Dis (2002) 1.05
Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease. Curr Pharm Des (2010) 1.04
A new molecular link between the fibrillar and granulovacuolar lesions of Alzheimer's disease. Am J Pathol (1999) 1.02
Mass spectrometric discovery and selective reaction monitoring (SRM) of putative protein biomarker candidates in first trimester Trisomy 21 maternal serum. J Proteome Res (2010) 1.02
Rapid Alzheimer-like phosphorylation of tau by the synergistic actions of non-proline-dependent protein kinases and GSK-3. FEBS Lett (1995) 0.96
Familial FTDP-17 missense mutations inhibit microtubule assembly-promoting activity of tau by increasing phosphorylation at Ser202 in vitro. J Biol Chem (2009) 0.96
p35/Cdk5 pathway mediates soluble amyloid-beta peptide-induced tau phosphorylation in vitro. J Neurosci Res (2002) 0.95
Casein kinase 1 is tightly associated with paired-helical filaments isolated from Alzheimer's disease brain. J Neurochem (1997) 0.95
Tau protein and the neurofibrillary pathology of Alzheimer's disease. Ann N Y Acad Sci (1996) 0.95
Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem (2003) 0.94
Functional implications of glycogen synthase kinase-3-mediated tau phosphorylation. Int J Alzheimers Dis (2011) 0.94
Direct analysis of tau from PSP brain identifies new phosphorylation sites and a major fragment of N-terminally cleaved tau containing four microtubule-binding repeats. J Neurochem (2008) 0.93
Drosophila models of human tauopathies indicate that Tau protein toxicity in vivo is mediated by soluble cytosolic phosphorylated forms of the protein. J Neurochem (2010) 0.93
Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des (2011) 0.91
Tau pathology and future therapeutics. Curr Alzheimer Res (2010) 0.88
c-jun N-terminal kinase hyperphosphorylates R406W tau at the PHF-1 site during mitosis. FASEB J (2006) 0.87
Phosphorylation of tau by glycogen synthase kinase 3beta in intact mammalian cells influences the stability of microtubules. Neurosci Lett (2001) 0.87
Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects. Curr Pharm Des (2011) 0.86
Blocking Effects of Human Tau on Squid Giant Synapse Transmission and Its Prevention by T-817 MA. Front Synaptic Neurosci (2011) 0.85
Involvement of puromycin-sensitive aminopeptidase in proteolysis of tau protein in cultured cells, and attenuated proteolysis of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) mutant tau. Psychogeriatrics (2009) 0.83
Tau phosphorylation and kinase activation in familial tauopathy linked to deln296 mutation. Neuropathol Appl Neurobiol (2003) 0.80
Disruption of neuronal function by soluble hyperphosphorylated tau in a Drosophila model of tauopathy. Biochem Soc Trans (2010) 0.77
The effect of cdk-5 overexpression on tau phosphorylation and spatial memory of rat. Sci China C Life Sci (2004) 0.76
A novel human primary immunodeficiency syndrome caused by deficiency of the endosomal adaptor protein p14. Nat Med (2006) 2.85
Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther (2011) 2.51
Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-κB-inducible immune pathways. Immunity (2011) 2.20
p14-MP1-MEK1 signaling regulates endosomal traffic and cellular proliferation during tissue homeostasis. J Cell Biol (2006) 2.15
Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology. Nat Med (2008) 2.01
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β. Nature (2012) 1.77
The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease. Neuron (2004) 1.71
Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J Biol Chem (2007) 1.68
Comparison of cellular ribonucleoprotein complexes associated with the APOBEC3F and APOBEC3G antiviral proteins. J Virol (2008) 1.37
Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase. J Neurosci (2005) 1.35
Lysosomal pathology associated with alpha-synuclein accumulation in transgenic models using an eGFP fusion protein. J Neurosci Res (2005) 1.30
Detection, quantitation, purification, and identification of cardiac proteins S-thiolated during ischemia and reperfusion. J Biol Chem (2002) 1.25
Phosphorylation of tau regulates its axonal transport by controlling its binding to kinesin. FASEB J (2008) 1.11
Cognition-enhancing properties of Dimebon in a rat novel object recognition task are unlikely to be associated with acetylcholinesterase inhibition or N-methyl-D-aspartate receptor antagonism. J Pharmacol Exp Ther (2010) 1.02
Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer's disease model. J Clin Neurosci (2010) 0.95
Inhibition of acyl-coenzyme A: cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway. FASEB J (2009) 0.94
A longitudinal study of behavioral deficits in an AβPP transgenic mouse model of Alzheimer's disease. J Alzheimers Dis (2011) 0.92
Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease. J Alzheimers Dis (2010) 0.92
Apolipoprotein A-I coating of protamine-oligonucleotide nanoparticles increases particle uptake and transcytosis in an in vitro model of the blood-brain barrier. J Control Release (2006) 0.92
Reversible cysteine-targeted oxidation of proteins during renal oxidative stress. J Am Soc Nephrol (2003) 0.91
Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice. Mol Neurodegener (2012) 0.90
EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials. J Mol Neurosci (2004) 0.90
Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease. Vaccine (2007) 0.90
A genome-wide RNAi screen in mouse embryonic stem cells identifies Mp1 as a key mediator of differentiation. J Exp Med (2011) 0.89
Identification and functional characterization of cytoplasmic determinants of plasmid DNA nuclear import. J Biol Chem (2009) 0.89
Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders? Curr Alzheimer Res (2007) 0.88
In vitro models of brain ischemia: the peptidergic drug cerebrolysin protects cultured chick cortical neurons from cell death. Neurotox Res (2002) 0.87
The acyl-coenzyme A: cholesterol acyltransferase inhibitor CI-1011 reverses diffuse brain amyloid pathology in aged amyloid precursor protein transgenic mice. J Neuropathol Exp Neurol (2010) 0.86
Purification and identification of the STAT5 protease in myeloid cells. Biochem J (2007) 0.85
Stability of the endosomal scaffold protein LAMTOR3 depends on heterodimer assembly and proteasomal degradation. J Biol Chem (2013) 0.85
Candidate verification of iron-regulated Neisseria meningitidis proteins using isotopic versions of tandem mass tags (TMT) and single reaction monitoring. J Proteomics (2009) 0.85
CaV1.2 calcium channel expression in reactive astrocytes is associated with the formation of amyloid-β plaques in an Alzheimer's disease mouse model. J Alzheimers Dis (2013) 0.84
Two-color, fluorescence-based microplate assay for apoptosis detection. Biotechniques (2002) 0.84
Localization and expression of substance P in transgenic mice overexpressing human APP751 with the London (V717I) and Swedish (K670M/N671L) mutations. Brain Res (2007) 0.84
L-type calcium channel CaV 1.2 in transgenic mice overexpressing human AbetaPP751 with the London (V717I) and Swedish (K670M/N671L) mutations. J Alzheimers Dis (2010) 0.83
Establishment of stably transfected rat neuronal cell lines expressing alpha-synuclein GFP fusion proteins. J Mol Neurosci (2009) 0.81
Beta-Synuclein-derived peptides with neuroprotective activity: an alternative treatment of neurodegenerative disorders? J Mol Neurosci (2004) 0.80
Tyrosine phosphorylation of tau by the SRC family kinases lck and fyn. Mol Neurodegener (2011) 0.80
Time course and progression of wild type α-synuclein accumulation in a transgenic mouse model. BMC Neurosci (2013) 0.80
Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory beta-synuclein-derived peptides. J Mol Neurosci (2002) 0.79
M6P/IGF2R modulates the invasiveness of liver cells via its capacity to bind mannose 6-phosphate residues. J Hepatol (2012) 0.79
The γ-secretase modulator CHF5074 reduces the accumulation of native hyperphosphorylated tau in a transgenic mouse model of Alzheimer's disease. J Mol Neurosci (2010) 0.79
Impact of ApoB-100 expression on cognition and brain pathology in wild-type and hAPPsl mice. Neurobiol Aging (2013) 0.79
Neuroinflammation and related neuropathologies in APPSL mice: further value of this in vivo model of Alzheimer's disease. J Neuroinflammation (2014) 0.78
Comparison of pharmacological modulation of APP metabolism in primary chicken telencephalic neurons and in a human neuroglioma cell line. J Mol Neurosci (2010) 0.78
Increased efflux of amyloid-β peptides through the blood-brain barrier by muscarinic acetylcholine receptor inhibition reduces pathological phenotypes in mouse models of brain amyloidosis. J Alzheimers Dis (2014) 0.78
In vivo and ex vivo imaging of amyloid-β cascade aggregates with a Pronucleon™ peptide. J Alzheimers Dis (2013) 0.78
Minimally Invasive Anterior Plate Osteosynthesis in Humeral Shaft Fractures. Eur J Trauma Emerg Surg (2008) 0.77
Non-selective calcium channel blocker bepridil decreases secondary pathology in mice after photothrombotic cortical lesion. PLoS One (2013) 0.77
Synthesis of monomeric derivatives to probe memoquin's bivalent interactions. J Med Chem (2011) 0.77
Characterization of proliferation and differentiation of EGF-responsive striatal and septal precursor cells. Int J Dev Neurosci (2003) 0.77
Chromogranin B and Secretogranin II in transgenic mice overexpressing human APP751 with the London (V717I) and Swedish (K670M/N671L) mutations and in Alzheimer patients. J Alzheimers Dis (2008) 0.77
Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study. Int Clin Psychopharmacol (2003) 0.77
Adamantane - A Lead Structure for Drugs in Clinical Practice. Curr Med Chem (2016) 0.76
A novel approach to selectively target neuronal subpopulations reveals genetic pathways that regulate tangential migration in the vertebrate hindbrain. PLoS Genet (2011) 0.76
A novel strategy using MASCOT Distiller for analysis of cleavable isotope-coded affinity tag data to quantify protein changes in plasma. Proteomics (2005) 0.76
Influence of Lentiviral β-Synuclein Overexpression in the Hippocampus of a Transgenic Mouse Model of Alzheimer's Disease on Amyloid Precursor Protein Metabolism and Pathology. Neurodegener Dis (2015) 0.76
The protective effect of ganstigmine against amyloid beta 25-35 neurotoxicity on chicken cortical neurons is independent from the cholinesterase inhibition. Neurosci Lett (2003) 0.75
The bivalent ligand approach as a tool for improving the in vitro anti-Alzheimer multitarget profile of dimebon. ChemMedChem (2013) 0.75
Preface. Neurodegener Dis (2016) 0.75
The 8th International Conference on Alzheimer's and Parkinson's Diseases. Preface. Neurodegener Dis (2008) 0.75
Preface. Neurodegener Dis (2010) 0.75